EP4426304A4 - Verfahren zur behandlung von abnormalem zellwachstum - Google Patents

Verfahren zur behandlung von abnormalem zellwachstum

Info

Publication number
EP4426304A4
EP4426304A4 EP22890990.9A EP22890990A EP4426304A4 EP 4426304 A4 EP4426304 A4 EP 4426304A4 EP 22890990 A EP22890990 A EP 22890990A EP 4426304 A4 EP4426304 A4 EP 4426304A4
Authority
EP
European Patent Office
Prior art keywords
treatment
cell growth
abnormal cell
abnormal
growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22890990.9A
Other languages
English (en)
French (fr)
Other versions
EP4426304A1 (de
Inventor
Brian M Stuglik
Andrew Koustenis
Jonathan A Pachter
Silvia Coma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verastem Inc
Original Assignee
Verastem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verastem Inc filed Critical Verastem Inc
Publication of EP4426304A1 publication Critical patent/EP4426304A1/de
Publication of EP4426304A4 publication Critical patent/EP4426304A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP22890990.9A 2021-11-02 2022-11-02 Verfahren zur behandlung von abnormalem zellwachstum Pending EP4426304A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163274745P 2021-11-02 2021-11-02
PCT/US2022/079109 WO2023081676A1 (en) 2021-11-02 2022-11-02 Methods of treating abnormal cell growth

Publications (2)

Publication Number Publication Date
EP4426304A1 EP4426304A1 (de) 2024-09-11
EP4426304A4 true EP4426304A4 (de) 2025-11-26

Family

ID=86242017

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22890990.9A Pending EP4426304A4 (de) 2021-11-02 2022-11-02 Verfahren zur behandlung von abnormalem zellwachstum

Country Status (10)

Country Link
US (1) US20240382485A1 (de)
EP (1) EP4426304A4 (de)
JP (1) JP2024542019A (de)
KR (1) KR20240093975A (de)
CN (1) CN118647382A (de)
AU (1) AU2022381730A1 (de)
CA (1) CA3236424A1 (de)
IL (1) IL312469A (de)
MX (1) MX2024005253A (de)
WO (1) WO2023081676A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7582694B2 (ja) 2020-01-10 2024-11-13 イミューニヤリング コーポレーション Ｍｅｋ阻害剤及びその治療的使用
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor
WO2024186693A1 (en) * 2023-03-03 2024-09-12 Immuneering Corporation Methods of treating cancer with a ras mutation
WO2025079712A1 (ja) * 2023-10-12 2025-04-17 中外製薬株式会社 ドライバー変異を有するがん患者における分子標的薬併用療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021704A1 (zh) * 2013-08-13 2015-02-19 天津国际生物医药联合研究院 多西环素在制备抗肿瘤药物中的应用
WO2019096397A1 (en) * 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8703781B2 (en) * 2009-10-16 2014-04-22 Glaxosmithkline Llc Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
US20170112865A1 (en) * 2014-05-21 2017-04-27 The Board Of Regents Of The University Of Texas System Treatment for melanoma
WO2021047783A1 (en) * 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
JP7582694B2 (ja) * 2020-01-10 2024-11-13 イミューニヤリング コーポレーション Ｍｅｋ阻害剤及びその治療的使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021704A1 (zh) * 2013-08-13 2015-02-19 天津国际生物医药联合研究院 多西环素在制备抗肿瘤药物中的应用
WO2019096397A1 (en) * 2017-11-16 2019-05-23 The Institute Of Cancer Research: Royal Cancer Hospital Coumarin derivative for therapy or prophylaxis of a cell proliferative disorder

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Verastem Oncology Announces Preliminary Data from Investigator-initiated Study Highlighting Clinical Activity of RAF/MEK and FAK Combination in KRAS Mutant Tumors Presented at the AACR 2020 Virtual Annual Meeting I", 27 April 2020 (2020-04-27), pages 1 - 6, XP093150355, Retrieved from the Internet <URL:https://www.clearityfoundation.org/verastem-oncology-announces-preliminary-data-from-investigator-initiated-study-highlighting-clinical-activity-of-raf-mek-and-fak-combination-in-kras-mutant-tumors-presented-at-the-aacr-2020-virtual-an/> [retrieved on 20240410] *
GUO CHRISTINA ET AL: "Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 11, 28 October 2020 (2020-10-28), pages 1478 - 1488, XP086334438, [retrieved on 20201028], DOI: 10.1016/S1470-2045(20)30464-2 *
I. MANOUSARIDIS ET AL: "Cutaneous side effects of inhibitors of the RAS/RAF/MEK/ERK signalling pathway and their management", JEADV , THE JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, vol. 27, no. 1, 1 January 2013 (2013-01-01), NL, pages 11 - 18, XP055235815, ISSN: 0926-9959, DOI: 10.1111/j.1468-3083.2012.04546.x *
LIU HUIJUAN ET AL: "Doxycycline Inhibits Cancer Stem Cell-Like Properties via PAR1/FAK/PI3K/AKT Pathway in Pancreatic Cancer", FRONTIERS IN ONCOLOGY, vol. 10, 1 February 2021 (2021-02-01), pages 619317, XP093298566, ISSN: 2234-943X, DOI: 10.3389/fonc.2020.619317 *
PESSI M A ET AL: "Targeted therapy-induced diarrhea: A review of the literature", CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY, vol. 90, no. 2, 5 December 2013 (2013-12-05), pages 165 - 179, XP028845254, ISSN: 1040-8428, DOI: 10.1016/J.CRITREVONC.2013.11.008 *
See also references of WO2023081676A1 *

Also Published As

Publication number Publication date
IL312469A (en) 2024-06-01
KR20240093975A (ko) 2024-06-24
WO2023081676A1 (en) 2023-05-11
MX2024005253A (es) 2024-05-14
EP4426304A1 (de) 2024-09-11
CN118647382A (zh) 2024-09-13
CA3236424A1 (en) 2023-05-11
AU2022381730A1 (en) 2024-05-02
US20240382485A1 (en) 2024-11-21
JP2024542019A (ja) 2024-11-13

Similar Documents

Publication Publication Date Title
EP4142882A4 (de) Verfahren zur behandlung von abnormalem zellwachstum
EP4178573A4 (de) Kombinationstherapie zur behandlung von abnormalem zellwachstum
EP4422617A4 (de) Kombinationstherapie zur behandlung von abnormalem zellwachstum
EP4426304A4 (de) Verfahren zur behandlung von abnormalem zellwachstum
EP4288057A4 (de) Kombinationstherapie zur behandlung von abnormalem zellwachstum
DE602006018354D1 (de) Verfahren zur behandlung von abnormalem zellwachstum
EP4444310A4 (de) Kombinationstherapie zur behandlung von abnormalem zellwachstum
EP4143204A4 (de) Verfahren zur behandlung von covid-19
EP4469086A4 (de) Kombinationstherapie zur behandlung von abnormalem zellwachstum
EP4441206A4 (de) Verfahren zur behandlung von akuter myeloischer leukämie
EP4003007C0 (de) Verfahren zur behandlung von schnittblumen
EP4181925A4 (de) Verfahren zur behandlung von proteinopathien
EP3945077C0 (de) Verfahren und system zur behandlung von biofeststoffen
EP4216962A4 (de) Line-1-inhibitoren zur behandlung von krankheiten
EP4444340A4 (de) Verfahren zur behandlung von krankheiten mit malt1-inhibitoren
EP3911348C0 (de) Verfahren zur behandlung von erkrankungen des zentralnervensystems
EP4225371A4 (de) Verfahren zur behandlung von ox40-verwandten krankheiten
EP4055062C0 (de) Verfahren zur behandlung von algen
EP4507713A4 (de) Verfahren zur behandlung von plakophillin-2-genen
EP4025218A4 (de) Verfahren zur behandlung
EP4034109A4 (de) Verfahren und zusammensetzung zur behandlung von erkrankungen
EP4522124A4 (de) Verfahren zur behandlung von urogenitalen gesundheitszuständen
EP4103592A4 (de) Verfahren zur abtötung oder hemmung des wachstums von krebszellen
EP3744852C0 (de) Verfahren und system zur behandlung von organischem material
EP4302957C0 (de) Verfahren zur behandlung von komplexen blättern

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240425

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40116577

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031506000

Ipc: A61K0031650000

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/65 20060101AFI20250731BHEP

Ipc: A61K 31/506 20060101ALI20250731BHEP

Ipc: A61K 45/06 20060101ALI20250731BHEP

Ipc: A61P 35/00 20060101ALI20250731BHEP

Ipc: A61P 43/00 20060101ALI20250731BHEP

Ipc: A61K 31/573 20060101ALI20250731BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20251027

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/65 20060101AFI20251021BHEP

Ipc: A61K 31/506 20060101ALI20251021BHEP

Ipc: A61K 45/06 20060101ALI20251021BHEP

Ipc: A61P 35/00 20060101ALI20251021BHEP

Ipc: A61P 43/00 20060101ALI20251021BHEP

Ipc: A61K 31/573 20060101ALI20251021BHEP